Diagnostics Articles
The U.S. Food and Drug Administration (FDA) has authorized the first over-the-counter combination COVID-19 and influenza test, the Healgen Rapid Check COVID-19/Flu A&B Antigen Test, outside of emergency use.
Researchers at the University of California, San Francisco, have identified a specific pattern of autoantibodies in the blood that precedes the clinical onset of multiple sclerosis.
A recent study has found that a commercially available plasma p-tau217 (phosphorylated tau 217) immunoassay accurately identified biological Alzheimer’s disease (AD).
A new study shows that a protein called glial fibrillary acidic protein is a possible biomarker for very early stages of Alzheimer's.
U.S. scientists have developed a new genomic test that can predict a patient's risk of developing severe COVID-19, an advance that could help doctors quickly begin tailored treatment.
FDA has given fast track approval for Bluebird Bio’s Zynteglo, a treatment designed to tackle the rare condition known as transfusion-dependent beta-thalassemia (TDBT).
A cross-disciplinary coalition of experts from academic centers across the United States is partnering with NIH, FDA, pharmaceutical companies and nonprofit organizations to identify new targets for therapies for autoimmune-meditated diseases.
A new study shows the Epstein-Barr virus (EBV) is essential for the development of multiple sclerosis (MS).
Kedrion Biopharma has created the free, easy-to-use KEDRAB Dose Calculator to help healthcare providers treat rabies exposures.
